Prelude announced it has decided to pause the clinical development of its SMARCA2 degrader program. The decision to pause was based on a comprehensive review of clinical data generated to date and the Company’s assessment of the capital and resource allocation required to advance the SMARCA2 program, versus the JAK2 and KAT6A programs, to key points of value inflection.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics announces publication of abstracts for ASH meeting
- Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
- Prelude Therapeutics Appoints Katina Dorton to Board
- Prelude Therapeutics appoints Katina Dorton to board of directors
- Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating